Indian generics slowly moving towards invention model but incentives are scant
In light of the recent headline-making Glivec decision, all eyes are now on the Indian pharmaceutical industry. Amidst all the clamour about whether or not India is anti-patent or if big pharma will look elsewhere to invest, no-one seems to be…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.